Background
Phase II, double-blind RCT (CheckMate 069) of 142 treatment-naive patients with advanced melanoma, randomized 2:1 and stratified by BRAF (V600) mutation status. Designed to assess the contribution of nivolumab added to ipilimumab.
Interventions and follow up
Arm A: ipilimumab 3 mg/kg + nivolumab 1 mg/kg every 3 weeks x4 doses, then nivolumab 3 mg/kg q2wk
Arm B: ipilimumab 3 mg/kg + placebo every 3 weeks x4 doses, then placebo
Primary endpoint: investigator-assessed ORR in BRAF wild-type patients
mFollow up: 11 months
Arm B: ipilimumab 3 mg/kg + placebo every 3 weeks x4 doses, then placebo
Primary endpoint: investigator-assessed ORR in BRAF wild-type patients
mFollow up: 11 months
Results
ORR BRAF wild-type: 61% vs 11%; P<.001
ORR BRAF-mutant: 52% vs 10%
CR rate (BRAF wild-type): 22% vs 0%
mPFS: not reached vs 4.4mo (arm A vs B); HR 0.40, 95% CI 0.23-0.68
ORR BRAF-mutant: 52% vs 10%
CR rate (BRAF wild-type): 22% vs 0%
mPFS: not reached vs 4.4mo (arm A vs B); HR 0.40, 95% CI 0.23-0.68
Adverse events
Overall (arm A vs B): grade 3-4 treatment-related AEs 54% vs 24%; discontinuation due to AEs 38% vs 13%
Most common (combination arm): colitis 17%, diarrhea 11%, elevated ALT 11%
Most common (combination arm): colitis 17%, diarrhea 11%, elevated ALT 11%
Conclusions
Combination nivolumab plus ipilimumab markedly increased objective response and prolonged progression-free survival versus ipilimumab alone in treatment-naive advanced melanoma, independent of BRAF mutation status, at the cost of substantially higher immune-related toxicity.
Key Limitations
Phase II with small sample (n=142); short follow-up and immature OS; comparator was ipilimumab monotherapy rather than nivolumab monotherapy, limiting assessment of each agent's individual contribution; high-grade immune toxicity and discontinuation rates.
Clinical Context
CheckMate 069 provided early evidence supporting combination ipilimumab plus nivolumab, contributing to FDA accelerated approval of the combination for advanced melanoma; the phase III CheckMate 067 subsequently confirmed benefit. ESMO guidelines endorse combination ipilimumab/nivolumab as a first-line option for advanced melanoma.